Calanus AS

Carnegie Investment Bank Norway is proud to have acted as financial adviser to Calanus AS in the private placement of NOK 100 million in new equity and an undisclosed secondary sale to Broodstock Capital.

Calanus is a biomarine industrial company from Northern Norway paving the way of development, production and sale of human and animal health supplements based on the large copepod, Calanus finmarchicus, one of the largest sustainable marine resources globally.

Carnegie congratulates former CEO and co-founder Gunnar Rørstad, CEO Siv-Katrin Ramskjell, CFO Roar Hausner, the shareholders and the rest of the Calanus team with the successful transaction. We look forward to continuing our support of Calanus going forward.

Related articles

Kebony
Investment Banking

Kebony

Carnegie Investment Bank Norway is proud to have acted as financial advisor in connection with Kebony’s successful...

Ultimovacs
Investment Banking

Ultimovacs

Carnegie Investment Bank Norway wishes to congratulate Ultimovacs on the NOK 270 million private placement completed on 27...

AutoStore
Investment Banking

AutoStore

Carnegie Investment Bank Norway is proud to have acted as Joint Global Coordinator and Joint Bookrunner...